Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Depreciation & Amortization (CF) (2022 - 2025)

TriSalus Life Sciences' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $126000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 34.72% year-over-year to $126000.0; the TTM value through Dec 2025 reached $626000.0, down 15.86%, while the annual FY2025 figure was $626000.0, 15.86% down from the prior year.
  • Depreciation & Amortization (CF) reached $126000.0 in Q4 2025 per TLSIW's latest filing, down from $163000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $194000.0 in Q4 2023 to a low of -$54000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $153846.2, with a median of $172000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 459.26% in 2023, then plummeted 34.72% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at -$54000.0 in 2022, then skyrocketed by 459.26% to $194000.0 in 2023, then fell by 0.52% to $193000.0 in 2024, then tumbled by 34.72% to $126000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Depreciation & Amortization (CF) are $126000.0 (Q4 2025), $163000.0 (Q3 2025), and $165000.0 (Q2 2025).